Results 31 to 40 of about 2,377 (150)

Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study. [PDF]

open access: yes, 2022
BACKGROUND Siponimod is a sphingosine 1-phosphate receptor modulator approved for active secondary progressive multiple sclerosis (aSPMS) in most countries; however, phase 3 EXPAND study data are from an SPMS population with/without disease activity ...
Fox, Robert J   +22 more
core   +2 more sources

Novel real world evidence from mSGo, a digital support program for secondary Progressive multiple sclerosis patients in Australia using siponimod

open access: yes, 2022
Introduction: Siponimod is approved in Australia for adults with secondary progressive multiple sclerosis (SPMS). Prescreen requirements for siponimod include a CYP2C9 genotype test to determine maintenance dosing. An integrated digital platform, ‘MSGo’,
Hardy, T   +15 more
core   +1 more source

Novel generation of real world evidence through MSGo, a digital support program supporting the use of siponimod in secondary progressive multiple sclerosis patients in Australia

open access: yes, 2021
Introduction: Siponimod is approved in Australia for adults with secondary progressive multiple sclerosis (SPMS). Initiating siponimod involves prescreening tests, including a CYP2C9 genotype test to determine siponimod maintenance dosing.
Hardy, T   +15 more
core   +1 more source

Novel Real World Evidence from MSGo, a Digital Support Program for Secondary Progressive Multiple Sclerosis Patients in Australia using Siponimod

open access: yes, 2023
Background: Siponimod is approved in Australia for adults with secondary progressive multiple sclerosis (SPMS). Prescreen requirements for siponimod include a CYP2C9 genotype test to determine maintenance dosing.
Broadley, Simon   +15 more
core   +1 more source

New possibilities for the therapy of secondary progressive multiple sclerosis

open access: yesНеврология, нейропсихиатрия, психосоматика, 2019
Patients with multiple sclerosis (MS) are at high risk for transition to secondary progressive MS (SPMS). To date, there has not been a sufficiently effective therapy for SPMS.
A. M. Petrov   +2 more
doaj   +1 more source

The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing–Remitting and Secondary Progressive Multiple Sclerosis

open access: yesDrugs in R&D, 2023
Multiple sclerosis (MS) is a chronic neurodegenerative disease that affects the central nervous system (CNS). Currently, MS treatment is limited to several Food and Drug Administration (FDA)- and European Medicines Agency (EMA)-approved medications that ...
Martin Vališ   +8 more
doaj   +1 more source

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

open access: yes, 2018
BACKGROUND: No treatment has consistently shown efficacy in slowing disability progression in patients with secondary progressive multiple sclerosis (SPMS).
Duquette, P   +651 more
core   +4 more sources

The first cases of using targeted therapy for secondary progressive multiple sclerosis in Russia. Case report

open access: yesConsilium Medicum, 2023
Siponimod (Kajendra) is a sphingosine-1-phosphate receptor modulator type 1 and 5 (S1P1,5), the first targeted agent for the treatment of patients with secondary progressive multiple sclerosis, both with and without exacerbations and/or activity ...
Denis S. Korobko   +3 more
doaj   +1 more source

Bioavailable central nervous system disease-modifying therapies for multiple sclerosis

open access: yesFrontiers in Immunology, 2023
Disease-modifying therapies for relapsing multiple sclerosis reduce relapse rates by suppressing peripheral immune cells but have limited efficacy in progressive forms of the disease where cells in the central nervous system play a critical role.
Hans-Peter Hartung   +8 more
doaj   +1 more source

Sphingosine-1-Phosphate (S1P) and S1P Signaling Pathway Modulators, from Current Insights to Future Perspectives

open access: yesCells, 2022
Sphingosine-1-phosphate (S1P) and S1P receptors (S1PR) are bioactive lipid molecules that are ubiquitously expressed in the human body and play an important role in the immune system.
Gary Álvarez Bravo   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy